{"id":"https://openalex.org/W4393988092","doi":"https://doi.org/10.1158/1538-7445.am2024-ct074","title":"Abstract CT074: ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)","display_name":"Abstract CT074: ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)","publication_year":2024,"publication_date":"2024-04-05","ids":{"openalex":"https://openalex.org/W4393988092","doi":"https://doi.org/10.1158/1538-7445.am2024-ct074"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2024-ct074","doi":"https://doi.org/10.1158/1538-7445.am2024-ct074","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2024-ct074","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika Hamilton","raw_affiliation_strings":["1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026459010","display_name":"Sung\u2010Bae Kim","orcid":"https://orcid.org/0000-0001-5588-8332","observed_orcids":["https://orcid.org/0000-0001-5588-8332"]},"institutions":[{"id":"https://openalex.org/I2801680663","display_name":"Asan Medical Center","ror":"https://ror.org/03s5q0090","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2801680663","https://openalex.org/I4210167194"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Sung-Bae Kim","raw_affiliation_strings":["2Asan Medical Center, Seoul, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Asan Medical Center, Seoul, Republic of Korea;","institution_ids":["https://openalex.org/I2801680663"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy U. Lin","raw_affiliation_strings":["3Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010064853","display_name":"Ahmad Hussein Awada","orcid":"https://orcid.org/0000-0001-7412-9163","observed_orcids":["https://orcid.org/0000-0001-7412-9163"]},"institutions":[{"id":"https://openalex.org/I2801838318","display_name":"Institut Jules Bordet","ror":"https://ror.org/05e8s8534","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2801838318"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Ahmad Awada","raw_affiliation_strings":["4Jules Bordet Cancer, Institute Brussels, Belgium;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Jules Bordet Cancer, Institute Brussels, Belgium;","institution_ids":["https://openalex.org/I2801838318"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076949146","display_name":"Eva Maria Ciruelos Gil","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101691","display_name":"Hospital Universitario 12 De Octubre","ror":"https://ror.org/00qyh5r35","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210101691","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Eva Ciruelos Gil","raw_affiliation_strings":["5Hospital Universitario 12 de octubre, Madrid, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Hospital Universitario 12 de octubre, Madrid, Spain;","institution_ids":["https://openalex.org/I4210101691"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011652422","display_name":"Alessandro Di Sanzo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessandro Di Sanzo","raw_affiliation_strings":["6Menarini Group, Florence, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Menarini Group, Florence, Italy;","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004289593","display_name":"Bartomeu Piz\u00e0 Vallespir","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Bartomeu Piza Vallespir","raw_affiliation_strings":["6Menarini Group, Florence, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Menarini Group, Florence, Italy;","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113726180","display_name":"Kathy Puyana Theall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265979","display_name":"Stemline Therapeutics (United States)","ror":"https://ror.org/034ms2s08","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108499","https://openalex.org/I4405265979"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathy Puyana Theall","raw_affiliation_strings":["7Stemline Therapeutics/Menarini Group, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Stemline Therapeutics/Menarini Group, New York, NY;","institution_ids":["https://openalex.org/I4405265979"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077026571","display_name":"Nuhad K. Ibrahim","orcid":"https://orcid.org/0000-0001-8660-243X","observed_orcids":["https://orcid.org/0000-0001-8660-243X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nuhad Ibrahim","raw_affiliation_strings":["8MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"7_Supplement","first_page":"CT074","last_page":"CT074"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11600","display_name":"Brain Metastases and Treatment","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/elacestrant","display_name":"elacestrant","score":0.9990000128746033},{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":1.0},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.7590000033378601},{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.9750000238418579},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/selective-estrogen-receptor-degrader","display_name":"selective estrogen receptor degrader","score":0.8610000014305115},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9769999980926514},{"id":"https://openalex.org/keywords/endocrine-resistance","display_name":"endocrine therapy resistance","score":0.7440000176429749},{"id":"https://openalex.org/keywords/blood-brain-barrier","display_name":"blood-brain barrier","score":0.7170000076293945},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.527999997138977},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.8109999895095825},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.671999990940094},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.36899998784065247},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7279999852180481},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.652999997138977},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.6480000019073486},{"id":"https://openalex.org/keywords/locally-advanced-or-metastatic-breast-cancer","display_name":"locally advanced or metastatic breast cancer","score":0.7239999771118164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7127225399017334},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.6590865850448608},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6217344999313354},{"id":"https://openalex.org/C2778164965","wikidata":"https://www.wikidata.org/wiki/Q1620196","display_name":"Brain metastasis","level":4,"score":0.608617901802063},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.5944018363952637},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5352246165275574},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5351067185401917},{"id":"https://openalex.org/C2777164284","wikidata":"https://www.wikidata.org/wiki/Q277954","display_name":"Estrogen","level":2,"score":0.48885291814804077},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.46078574657440186},{"id":"https://openalex.org/C2910363380","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"HER2 negative","level":5,"score":0.4350310266017914},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.35049280524253845}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2024-ct074","doi":"https://doi.org/10.1158/1538-7445.am2024-ct074","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2024-ct074","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4396599588","https://openalex.org/W7162683890","https://openalex.org/W4399323814","https://openalex.org/W4402561258","https://openalex.org/W7201837283","https://openalex.org/W4411287765","https://openalex.org/W4411288372","https://openalex.org/W4399323640","https://openalex.org/W7129252518","https://openalex.org/W4322774064"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Endocrine":[2],"therapy":[3,223],"(ET)":[4],"+":[5],"cyclin":[6],"dependent":[7],"kinase":[8],"4/6":[9],"inhibitor":[10],"(CDK4/6i)":[11],"is":[12,132,162,197,248,285,312],"the":[13,16,36,64,129,148,152,192,225,251,310,317,380],"mainstay":[14],"for":[15,117,128,200,383],"management":[17],"of":[18,58,77,92,98,194,268,303,309,356,379],"ER+/HER2-":[19,120,179],"mBC":[20],"as":[21],"1st-line":[22],"therapy.":[23],"However,":[24],"tumors":[25],"eventually":[26],"develop":[27],"resistance":[28],"to":[29,32,63,133,150,249,315],"ET,":[30,61],"leading":[31,62],"disease":[33],"progression.":[34],"In":[35],"EMERALD":[37],"phase":[38,165,190,203,244,253,281,306,353],"3":[39],"trial,":[40],"single-agent":[41],"elacestrant":[42,71,102,135,170,357],"was":[43],"associated":[44],"with":[45,83,101,106,119,136,140,173,178,319,360,364],"significantly":[46],"prolonged":[47],"progression-free":[48],"survival":[49,278],"(PFS)":[50],"and":[51,185,211,237,276,301,394],"a":[52,73,96],"manageable":[53],"safety":[54],"profile":[55],"vs":[56,80,103],"standard":[57],"care":[59],"(SOC)":[60],"first":[65],"oral":[66],"SERD":[67],"approval.":[68],"Patients":[69,87,218],"receiving":[70],"experienced":[72,95],"median":[74],"PFS":[75],"(mPFS)":[76],"3.8":[78],"months":[79,82,91,100,105],"1.9":[81,104],"SOC":[84,107],"(Bidard,":[85],"2022).":[86,109],"who":[88,122],"received":[89,221],"\u226512":[90],"prior":[93,222,239],"CDK4/6i":[94,240],"mPFS":[97],"8.6":[99],"(SABCS,":[108],"Currently,":[110],"there":[111],"are":[112],"no":[113],"approved":[114],"systemic":[115],"treatments":[116],"patients":[118,139,177,205,363],"BC":[121,184],"have":[123,146,207,220],"brain":[124,141,187,195,213,365],"metastasis.":[125,188],"The":[126,243,280,305],"rationale":[127],"ELECTRA":[130,160],"study":[131,168,320,355],"combine":[134],"abemaciclib":[137,361],"in":[138,171,224,358,362],"metastasis,":[142],"given":[143],"both":[144],"compounds":[145],"demonstrated":[147],"ability":[149],"cross":[151],"blood-brain":[153],"barrier":[154],"(Conlan,":[155],"2020;":[156],"Tolaney,":[157],"2020).":[158],"Methods:":[159],"(NCT05386108)":[161],"an":[163],"open-label":[164],"1b/2,":[166],"multicenter":[167],"evaluating":[169],"combination":[172,359],"abemaciclib.":[174],"Eligibility":[175],"includes":[176],"locally":[180],"advanced":[181],"or":[182],"metastatic":[183,226],"measurable":[186,212],"For":[189,202],"1b,":[191],"presence":[193],"metastasis":[196,214,366],"not":[198],"required":[199],"eligibility.":[201],"2,":[204],"must":[206,219],"\u2265":[208,229],"1":[209,230],"active":[210],"per":[215,287],"RECIST":[216,288],"v1.1.":[217],"setting,":[227],"including":[228],"endocrine":[231],"therapy,":[232],"\u2264":[233],"2":[234,254,282,390],"chemotherapy":[235],"regimens,":[236],"0-2":[238],"(excluding":[241],"abemaciclib).":[242],"1b":[245,307],"primary":[246,283],"objective":[247,284],"determine":[250,316],"recommended":[252],"dose":[255],"(RP2D);":[256],"secondary":[257,290],"objectives":[258,291],"include":[259,292],"safety,":[260],"pharmacokinetics":[261],"(PK),":[262],"overall":[263,277],"response":[264,269,294],"rate":[265,273],"(ORR),":[266],"duration":[267],"(DoR),":[270],"clinical":[271],"benefit":[272],"(CBR),":[274],"PFS,":[275,298],"(OS).":[279],"ORR":[286],"v1.1;":[289],"intracranial":[293],"rate,":[295],"DoR,":[296],"CBR,":[297],"OS,":[299],"PK,":[300],"quality":[302],"life.":[304],"portion":[308],"trial":[311],"actively":[313],"ongoing":[314],"RP2D":[318],"sites":[321],"open":[322],"worldwide.":[323],"Citation":[324],"Format:":[325],"Erika":[326],"Hamilton,":[327],"Sung-Bae":[328],"Kim,":[329],"Nancy":[330],"U.":[331],"Lin,":[332],"Ahmad":[333],"Awada,":[334],"Eva":[335],"Ciruelos":[336],"Gil,":[337],"Alessandro":[338],"Di":[339],"Sanzo,":[340],"Bartomeu":[341],"Piza":[342],"Vallespir,":[343],"Kathy":[344],"Puyana":[345],"Theall,":[346],"Nuhad":[347],"Ibrahim.":[348],"ELECTRA:":[349],"An":[350],"open-label,":[351],"multicenter,":[352],"1b/2":[354],"from":[367],"estrogen":[368],"receptor-positive":[369],"(ER+),":[370],"HER2-negative":[371],"(HER2-)":[372],"breast":[373],"cancer":[374],"(BC)":[375],"[abstract].":[376],"In:":[377],"Proceedings":[378],"American":[381],"Association":[382],"Cancer":[384,406],"Research":[385],"Annual":[386],"Meeting":[387],"2024;":[388],"Part":[389],"(Late-Breaking,":[391],"Clinical":[392],"Trial,":[393],"Invited":[395],"Abstracts);":[396],"2024":[397],"Apr":[398],"5-10;":[399],"San":[400],"Diego,":[401],"CA.":[402],"Philadelphia":[403],"(PA):":[404],"AACR;":[405],"Res":[407],"2024;84(7_Suppl):Abstract":[408],"nr":[409],"CT074.":[410]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-04-06T00:00:00"}